Join
Live feed
·
PRReleasevia Quantisnow
Biogen Inc. logo
Stoke Therapeutics Inc. logo

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
BIIB· Biogen Inc.STOK· Stoke Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIIB (Biogen Inc.), STOK (Stoke Therapeutics Inc.) and more on Quantisnow.